Semaglutide vs Tirzepatide for PCOS: How the Published Studies Compare

If you have PCOS and are considering a GLP-1 receptor agonist for the weight and insulin-resistance components, the practical choice usually comes down to two medications: semaglutide and tirzepatide. Both are FDA-approved for chronic weight management in the general adult population (under different brand names), both are used off-label in PCOS, and both have growing PCOS-specific evidence bases. They are not interchangeable. Choosing between them is a real clinical decision — one a licensed clinician makes with you, weighing your full clinical picture, with real consequences for side effects and cost.

This post compares how the published studies characterize the two molecules — on mechanism, PCOS-specific evidence, weight-loss magnitude, secondary endpoints (insulin, androgens, cycles), side effects, dosing, and cost. Nothing here is a recommendation for you specifically; the goal is to give you enough framework that the conversation you have with your clinician about which medication to start is a real conversation, not a one-sided pitch. The choice itself is your clinician's, made on your full picture.

Mechanism — same family, different details

Semaglutide is a single-receptor agonist: it binds and activates the GLP-1 receptor. The downstream effects are familiar — glucose-dependent insulin secretion, suppressed glucagon, slowed gastric emptying, and central appetite suppression. Semaglutide is administered as a weekly subcutaneous injection.

Tirzepatide is a dual-receptor agonist: it binds and activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is the other major incretin hormone. The two-receptor mechanism produces somewhat larger effects on weight loss and glucose handling than GLP-1 alone — head-to-head trials in type 2 diabetes and in obesity (without PCOS) have consistently shown tirzepatide outperforming semaglutide on weight loss and glycemic markers.

In PCOS specifically, the mechanism question is whether the dual-receptor activation adds anything beyond the insulin-resistance and weight effects you would get from semaglutide alone. The honest answer is: probably, in patients who tolerate the higher doses, but the PCOS-specific head-to-head dataset is still small. The general weight-loss and glucose data suggests yes. Whether the PCOS-specific endpoints (androgens, cycles, ovulation) follow the same pattern has not yet been established — head-to-head PCOS data does not exist.

Weight loss — where the magnitudes differ

In general-population trials of the FDA-approved branded products, semaglutide produced approximately 15–17% body-weight reduction at maximum tolerated dose over 68 weeks, and tirzepatide approximately 20–22% over similar durations. That difference has been consistent across trials. These are trial averages for approved products — not compounded formulations — and are not predictions for any individual; individual results vary.

In PCOS specifically, one of the largest datasets to date is the UK real-world tirzepatide cohort: 4,241 women with PCOS prescribed branded tirzepatide between February 2024 and January 2025. Median weight loss was reported as 18.81% at ten months, with 90.8% reaching at least 10% loss and 75.96% reaching at least 15%. That is one of the largest PCOS-specific datasets published to date. As with any real-world cohort, the numbers describe the studied population — they are not predictions for any individual; the cohort used branded tirzepatide, not compounded formulations, and individual responses vary widely.

Semaglutide PCOS-specific cohorts and trials have typically reported 10–15% weight loss at six months — a different timeframe and a different magnitude. The Jensterle 2023 RCT (16 weeks, 1.0 mg weekly) and subsequent semaglutide PCOS studies have shown smaller weight loss than the UK tirzepatide cohort, partly because the trial durations were shorter and partly because the medication produces less weight loss on average. Both medications have published PCOS-specific data; the reported magnitudes differ.

For a patient with significant weight to lose, that magnitude difference can matter clinically. For a patient near a healthy BMI who is on GLP-1 primarily for insulin and cycle benefits, the magnitude is less central — and a clinician might lean toward semaglutide on tolerability or cost.

Secondary endpoints — insulin, androgens, cycles

In published PCOS studies, participants receiving GLP-1 medications showed improvements in insulin sensitivity and in androgen markers such as free testosterone. The Abdalla et al. systematic review (European Journal of Endocrinology, 2026) pooled 11 RCTs and reported a BMI reduction of −1.38 kg/m² versus control; the same literature describes the evidence on menstrual regularity and ovulation as limited. These are study averages in trials of non-compounded medications, and they are not predictions for any individual.

The pooled data is mostly semaglutide and liraglutide because the PCOS-specific tirzepatide trial dataset is still being published. What can be said with confidence:

• Insulin sensitivity: Published PCOS studies have reported meaningful improvements in HOMA-IR and fasting insulin with both medications. Tirzepatide's GIP-receptor activation may give it a slight edge in glucose handling, especially in patients with concurrent prediabetes or type 2.
• Free testosterone: In the studied populations, both medications reduced free testosterone, mediated through insulin reduction and SHBG increase. The magnitude tracked the magnitude of weight loss and insulin improvement.
• Cycle regularity: Studies report improved cycle regularity in both groups, with the largest improvements among participants who reached at least 10% body-weight loss — a threshold reached more often in the tirzepatide cohorts studied.

For a PCOS phenotype dominated by metabolic dysfunction (high HOMA-IR, prediabetes, significant weight), clinicians often note that tirzepatide's dual mechanism acts more aggressively on the metabolic axis. Where the phenotype is dominated by androgens with milder metabolic features, both medications have supportive published data, and clinicians often weigh tolerability and cost more heavily.

Side effects — same class, slight pattern differences

The side-effect profile is the same class profile: nausea (20–40% across both medications), occasional vomiting and constipation, slowed gastric emptying, rare gallbladder events, rare pancreatitis, and the boxed warning for medullary thyroid carcinoma in patients with personal or family MEN-2 history. Neither medication is appropriate during pregnancy or breastfeeding.

Real-world experience suggests some pattern differences:

• Tirzepatide users frequently describe somewhat better tolerability at low doses than semaglutide users at comparable points in titration — possibly because the dual-receptor mechanism produces a different curve of GI effects.
• Tirzepatide at higher doses (12.5 mg, 15 mg) can produce more pronounced nausea than semaglutide at comparable trial-curve doses.
• The slowed gastric emptying is more pronounced on the higher tirzepatide doses, which is relevant to oral contraceptive absorption (more on this below).

For PCOS patients on oral contraceptives this is one of the few places the two drugs differ in a way that matters, and the guidance is not the same for both.

Tirzepatide carries a specific labeled interaction: because it delays gastric emptying, it can reduce the absorption of oral hormonal contraceptives. The labeling advises switching to a non-oral contraceptive method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.

Semaglutide labeling reports no clinically relevant effect on oral-contraceptive exposure, and does not carry that instruction.

If you are on the pill and relying on it, raise this with your clinician before starting either medication — the answer is drug-specific.

Cost — direct-pay reality

Brand-name pricing in the U.S. for semaglutide and tirzepatide products is in the $1,000–1,300 per month range without insurance, and insurance coverage for off-label PCOS use is rare. The direct-pay compounded path has been the practical access point for most PCOS patients.

At TelePeptide, compounded semaglutide is $199 per month and compounded tirzepatide is $249 per month, billed monthly (from $169 and $214 per month on the 52-week prepay). Those prices include the medication; clinician visits, labs, and supplies are separate (or included in the program depending on the tier). The $50 monthly difference between the two medications is real but small relative to the brand pricing it replaces. For most patients the choice is not driven by the price gap — it is driven by the magnitude of weight loss needed, side-effect tolerance, and what the clinician thinks fits the individual.

Compounded medications are prepared by licensed 503A pharmacies under individual prescriptions. They are not FDA-approved and are not equivalent to the brand-name FDA-approved drugs.

How clinicians choose

The clinical choice between semaglutide and tirzepatide for PCOS is rarely formulaic. Factors clinicians commonly weigh:

1. Magnitude of weight loss needed. If the patient is significantly above their target weight and the goal is to reach the ≥10% body-weight threshold where the largest PCOS benefits cluster, tirzepatide's larger effect size makes it the more efficient tool. If the patient is only moderately overweight or has a lean PCOS phenotype, semaglutide is often sufficient.

2. Side-effect history. Patients who have tolerated semaglutide poorly in the past sometimes do better on tirzepatide and vice versa. There is no reliable predictor — both medications get tried in real-world practice.

3. Concurrent prediabetes or type 2. Tirzepatide's dual-receptor activation has produced larger glycemic improvements in head-to-head trials. If glucose is a significant part of the picture, the clinician usually leans tirzepatide.

4. TTC timeline. Both medications are stopped before conception. Semaglutide labeling specifies at least 2 months before a planned pregnancy. Tirzepatide labeling specifies no interval, so its washout is a clinical judgement rather than a published number — which means it is not a reliable basis for choosing between the two. If TTC is on the near horizon, have the fertility-planning conversation with your clinician rather than picking a drug on washout length.

5. Cost sensitivity. If the $50 monthly difference matters to the patient's budget, semaglutide is the cheaper option and is fully appropriate for the majority of PCOS patients.

6. Microdose appropriateness. Both medications can be used at microdose levels. Semaglutide microdosing has a longer informal track record — that may be a marginal factor for patients pursuing the gentlest possible on-ramp.

Where clinicians tend to land

For patients with significant weight to lose and a metabolic-dominant phenotype, clinicians often weigh tirzepatide's larger published effect sizes heavily — the magnitude data is the strongest, the metabolic mechanism is the most aggressive, and the real-world PCOS cohort is the largest.

For patients with mild metabolic dysfunction, near-normal weight, or significant cost sensitivity, semaglutide's longer PCOS-specific track record and lower cost may dominate, and it is an equally clinically reasonable option.

In most cases there is no wrong answer — there is a better-fit answer for the individual patient. That choice is individualized and made by a licensed clinician, not by an article and not by you alone.

---

Disclaimer: This article is education, not medical advice. Compounded medications are not FDA-approved, and GLP-1 use for PCOS is off-label. Any treatment decision is made solely by a licensed clinician after an individualized evaluation. Individual results vary — no outcome is guaranteed.

---

Editorial note: TelePeptide (the company) is a US direct-pay telehealth practice offering clinician-supervised compounded peptide therapy in 48 US states + DC. The brand name is sometimes autocorrected to "telopeptide" — an unrelated collagen biomarker; the two terms have no clinical connection.